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Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease, best characterized by the
formation of proliferative nodules that express smooth muscle and melanocytic antigens
within the lung parenchyma, leading to progressive destruction of lung tissue and function.
The pathological basis of LAM is associated with Tuberous Sclerosis Complex (TSC), a
multi-system disorder marked by low-grade tumors in the brain, kidneys, heart, eyes,
lung and skin, arising from inherited or spontaneous germ-line mutations in either of
the TSC1 or TSC2 genes. LAM can develop either in a patient with TSC (TSC-LAM) or
spontaneously (S-LAM), and it is clear that the majority of LAM lesions of both forms are
characterized by an inactivating mutation in either TSC1 or TSC2, as in TSC. Despite this
genetic commonality, there is considerable heterogeneity in the tumor spectrum of TSC
and LAM patients, the basis for which is currently unknown. There is extensive clinical
evidence to suggest that the cell of origin for LAM, as well as many of the TSC-associated
tumors, is a neural crest cell, a highly migratory cell type with extensive multi-lineage
potential. Here we explore the hypothesis that the types of tumors that develop and the
tissues that are affected in TSC and LAM are dictated by the developmental timing of
TSC gene mutations, which determines the identities of the affected cell types and the
size of downstream populations that acquire a mutation. We further discuss the evidence
to support a neural crest origin for LAM and TSC tumors, and propose approaches for
generating humanized models of TSC and LAM that will allow cell of origin theories to be
experimentally tested. Identifying the cell of origin and developing appropriate humanized
models is necessary to truly understand LAM and TSC pathology and to establish effective
and long-lasting therapeutic approaches for these patients.
Keywords: Lymphangioleiomyomatosis, Tuberous Sclerosis, neural crest, cell of origin, disease modeling
INTRODUCTION
CLINICAL FEATURES IN TSC AND LAM REVEAL A HETEROGENEOUS
DISEASE SPECTRUM
Tuberous sclerosis complex (TSC) is a multisystem disorder
that arises as a consequence of inherited or spontaneously
acquired mutations in either the TSC1 or TSC2 gene. Along with
Neurofibromatosis type 1, TSC is among the most common neu-
rocutaneous diseases, occurring in an estimated 1 in 6000 births
(Kandt, 2003; Kristof and Moss, 2011). TSC affects both children
and adults, often with clinical manifestations initiating during
embryonic development, accompanied by the gradual presen-
tation of additional symptoms throughout childhood and into
adulthood. Clinical features of TSC (Figure 1) include the appear-
ance of low-grade tumors and malformations in the brain, heart,
lungs, kidneys, eyes, skin, and bone, and loss of heterozygosity
or second-hit mutations of the wild-type TSC1 or TSC2 allele
are thought to be responsible for the formation of most of these
lesions (Henske et al., 1996; Carsillo et al., 2000; Crino et al., 2010;
Qin et al., 2010a, 2011; Tyburczy et al., 2014). Cortical tubers are
prevalent in TSC and account for the majority of the debilitative
neurological symptoms, including epilepsy, mental retardation
and autism (Webb et al., 1996; Goh et al., 2005; Crino et al.,
2006; Wong, 2006; Crino and Tsai, 2012). Tubers, along with car-
diac rhabdomyomas, are formed during embryogenesis and can
be detected prenatally (Park et al., 1997), whereas other tumors
and lesions form during childhood and into adulthood. These
include retinal astrocytomas, subependymal giant cell astrocy-
tomas (SEGAs), angiofibromas and hypomelanotic macules in
the skin, sub-ependymal nodules/giant-cell tumors, and renal
angiomyolipomas (AMLs).
TSC is also associated with pulmonary and lymphatic man-
ifestations in the form of Lymphangioleiomyomatosis (LAM), a
progressive neoplasm of the lung that occurs in at least 30% of
women with TSC (TSC-LAM), with an average age of diagnosis
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FIGURE 1 | The clinical manifestations of TSC and LAM are diverse
and affect multiple organs and tissues. The major diagnostic
features of TSC are indicated in bold type (Northrup et al., 2013).
Cortical tubers and cardiac rhabdomyomas occur during fetal
development. Facial angiofibromas, hypomelanic macules, and retinal
astrocytic hamartomas can be detected in infancy, while the other
features continue to present themselves throughout development into
adulthood.
of about 35 years (Henske and McCormack, 2012). LAM is
characterized by the presence of multiple neoplastic nodules
within the lung interstitium, composed of proliferating smooth
muscle-like cells and abnormally large epithelial cells that express
melanocytic markers. The proliferative LAM nodules form cys-
tic lesions within the lungs, which lead to the destruction of the
parenchyma, resulting in progressive shortness of breath, chylous
pleural effusions, pneumothorax, and eventual respiratory failure
(Kitaichi et al., 1995; Chu et al., 1999; Urban et al., 1999).
LAM can also occur in a sporadic form (S-LAM), where
lung lesions and associated renal and lymphatic manifestations
are similar to those observed in TSC patients, but other TSC-
associated tumors are absent (Costello et al., 2000; Moss et al.,
2001). In addition to pulmonary manifestations, other com-
mon features of LAM include lymphatic abnormalities, such
as lymphadenopathy (Chu et al., 1999; Urban et al., 1999),
renal AMLs, and uterine PEComas (Perivascular Epitheloid Cell
tumors). AMLs are benign growths composed of adipocytes and,
much like their pulmonary counterparts, smooth muscle cells,
and are asymptomatic in most cases (Bissler and Kingswood,
2004). Uterine PEComas are, curiously, also characterized by cells
of an epithelial morphology that express smooth muscle and
melanocytic markers, similar to the cells that comprise LAM lung
nodules (Martignoni et al., 2007; Hayashi et al., 2011; Henske and
McCormack, 2012). Thus, TSC is associated with the develop-
ment of a broad spectrum of pathological lesions, affecting a wide
diversity of tissues and cell types.
GENETIC FEATURES IN LAM AND TSC
TSC, TSC-LAM, and S-LAM patients typically possess inacti-
vating mutations in TSC1 or, much more commonly, TSC2
(Smolarek et al., 1998; Carsillo et al., 2000; Sato et al., 2002). Loss
of heterozygosity in either of these genes from second-hit muta-
tions is thought to be important in driving tumor development
(Green et al., 1994; Sepp et al., 1996; Niida et al., 2001; Han et al.,
2004; Henske and McCormack, 2012). According to the Leiden
Open Variation Database (Fokkema et al., 2011), as of 2014 there
are over 680 and 1500 reported unique pathogenic DNA vari-
ants in TSC1 and TSC2, respectively. The wide array of mutations
spans all exons of both TSC1 and TSC2, with no specificity for
any particular coding region or mutation type, and includes a
number of mutation types [such as genomic deletions, missense
and non-sense mutations and protein truncations (Cheadle et al.,
2000; Crino et al., 2006; Au et al., 2007)]. Although mutations in
either of these genes lead to the development of disease features,
extensive genotype-phenotype analysis has been performed and
found that mutations in TSC2 are associated with more severe
phenotypes than are mutations in TSC1 (Niida et al., 1999; van
Slegtenhorst et al., 1999; Au et al., 2007).
Intriguingly, the genetic features in S-LAM patients mirror
those of TSC patients, but pathological manifestations in S-LAM
are limited to those in the lung, kidneys, lymphatics, liver and
uterus (Henske and McCormack, 2012), and TSC gene muta-
tions in S-LAM patients are not wide-spread or found within the
germline (Astrinidis et al., 2000). Currently, the conditions that
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underlie the heterogeneity in the disease spectrum between TSC
and LAM patients are unknown. Clinical observations, and some
experimental evidence, offer clues, however, that the cell of origin
in concert with the developmental timing of TSC1 or TSC2muta-
tion are likely key factors in determining which disease features
ultimately manifest.
MOLECULAR CHARACTERISTICS OF TSC AND LAM LESIONS
Aberrant mTOR signaling broadly characterizes TSC lesions
TSC and LAM lesions are believed to share the common fea-
ture of elevated mTOR pathway signaling, ultimately as a con-
sequence of inactivating mutations in TSC1 or TSC2 (Green
et al., 1994; Niida et al., 2001; Han et al., 2004; Henske and
McCormack, 2012). The TSC1 and TSC2 genes encode Hamartin
and Tuberin, respectively, which form heterodimers and inhibit
the GTPase activity of the Ras homolog Rheb, a direct activa-
tor of the Mammalian Target of Rapamycin (mTOR). mTOR
signals through two macromolecular complexes, mTORC1 and
mTORC2, to integrate the external environment (growth factor
stimulation, cellular stress, oxygen availability, energy and nutri-
ent levels) with diverse cellular functions, including proliferation,
survival, growth and size, death and autophagy, protein transla-
tion, angiogenesis, movement, and migration. TSC1 and TSC2
function as critical gatekeepers of this multi-functional cellular
signaling network.
The therapeutic efficacy of Rapamycin, a molecular inhibitor
of mTOR, in treating many of the manifestations in TSC and
LAM (Franz et al., 2006; Bissler et al., 2008; Krueger et al., 2010;
Micozkadioglu et al., 2010; Casanova et al., 2011; Dabora et al.,
2011; DeKlotz et al., 2011; McCormack et al., 2011; Tiberio et al.,
2011; Canpolat et al., 2014; Park et al., 2014) has established ele-
vated mTOR signaling as a key feature driving these tumors. The
cells that comprise LAM and TSC tumors reflect many features of
hyper-active mTOR signaling: abnormally large or “giant” cells,
altered morphology, aberrant migration, abnormal proliferation,
increased cell survival and reduced autophagy are common fea-
tures of many lesions (Crino, 2004; Crino and Tsai, 2012; Henske
and McCormack, 2012). Increased angiogenesis is also a feature
of many TSC lesions, including LAM (Nguyen-Vu et al., 2001;
Arbiser et al., 2002; Kumasaka et al., 2004; Li et al., 2013).
Unique molecular characteristics distinguish TSC-associated
lesions
Despite the common element of hyperactive mTOR signaling,
the types of lesions that develop in TSC and LAM are diverse,
in terms of both the tissues that are affected and the molecu-
lar characteristics of the aberrant cells. Furthermore, different
types of TSC-associated tumors exhibit additional behavioral
and signaling characteristics that are distinct from one another.
For example, LAM cells are uniquely responsive to estrogen and
prolactin signaling, and express these receptors on their sur-
face (Terasaki et al., 2010; Gao et al., 2014)(reviewed in Yu and
Henske, 2010). They also express markers of smooth muscle cells
and melanocytes, cell types not normally found throughout the
lung interstitium.
Alternatively, the aberrant cells that comprise cortical tubers
and SEGAs in TSC patients express markers of early neuronal and
glial cell differentiation (Lopes et al., 1996; Ess et al., 2005; Zhou
et al., 2011) and recent mouse models have clarified that these
tumors can result from mTOR-dependent promotion of aberrant
neural progenitor cell (NPC) expansion and premature differ-
entiation, accompanied by defective maturation and abnormal
migration (Magri et al., 2011; Magri and Galli, 2013). Thus, in the
TSC lesions confined to the CNS, mTOR hyper-activation leads
to a direct reprogramming of the self-renewal and differentiation
capacity of the cells endogenous to the tissue in which the lesions
are found, while the etiology of mTOR hyper-activation to the
appearance of LAM-associated lesions in the lung, kidneys, and
uterus is much less clear. TSC and LAM are further differentiated
by the time-point of disease presentation, where most TSC fea-
tures typically present in infancy or during childhood and LAM
presents in adulthood. These differences suggest that, despite their
common genetic characteristic, distinct TSC and LAM lesions
exhibit unique pathological mechanisms.
POTENTIAL CELLS OF ORIGIN FOR TSC AND LAM
The cell(s) of origin for TSC and LAM lesions are largely
unknown, however clinical observations and limited experimen-
tal evidence have offered some key clues. The extensive multi-
system involvement in these diseases is remarkable, and while
there is evidence for both common and independent second-hit
TSC1 or TSC2 mutations across multiple tumors within a given
individual (Henske et al., 1996; Smolarek et al., 1998; Carsillo
et al., 2000; Karbowniczek et al., 2003; Tyburczy et al., 2014), a
single first-hit mutation appears to characterize all of a patients’
tumors. The lesions that commonly arise in TSC are generally
comprised of immature cells that exhibit molecular and behav-
ioral features of either neuronal (central nervous system (CNS)
lesions) or mesenchymal differentiation. While embryonic neu-
ral stem cells (NSCs) appear to function as a cell of origin for the
CNS manifestations in TSC (discussed further below), the mes-
enchymal neural crest lineage has been postulated to broadly give
rise to other types of lesions in TSC and LAM.
With the potential involvement of both NSCs and the neural
crest lineage in disease heterogeneity, the influence of the devel-
opmental time-point at which TSC1 or TSC2 mutations occur
on disease severity has also been called into question. However,
these theories have not been experimentally confirmed, and no
animal or humanized model currently exists to directly test these
suppositions. Here, we explore the evidence supporting the cell
of origin hypotheses that have emerged from the TSC and LAM
field, and, based on these theories, we further propose approaches
for generating relevant humanized models of TSC and LAM that
will enable the identification of improved therapeutic avenues and
open the door for patient-centered approaches to treatment.
EXPERIMENTAL EVIDENCE THAT NEURAL STEM CELLS DRIVE CNS
PATHOLOGY IN TSC
Mouse models of TSC gene deficiency in the CNS
Experimental approaches to identify the cell of origin in TSC
have focused to date almost exclusively on validating the hypoth-
esis that the CNS tumors and behavioral phenotypes are driven
by TSC1 or TSC2 mutations in the NSC lineage. Since the CNS
manifestations cause significant morbidity and are apparent at
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such a young age, this focus is not surprising. As mouse mod-
els of both TSC1- and TSC2-deficiency using gene targeting lead
to early embryonic lethality, and mice heterozygous for either
TSC gene do not develop TSC-related CNS pathologies (likely
due to the absence of a second-hit mutation during embry-
onic development) (Kobayashi et al., 1999, 2001; Onda et al.,
1999; Kwiatkowski et al., 2002), more sophisticated models have
recently emerged to assess the effects of homozygous TSC gene
mutation in select populations of NPCs and differentiating or dif-
ferentiated neuronal cells (Uhlmann et al., 2002; Meikle et al.,
2007; Ehninger et al., 2008; Way et al., 2009; Goto et al., 2011;
Magri et al., 2011; Zeng et al., 2011; Zhou et al., 2011; Carson
et al., 2012; Feliciano et al., 2012, 2011; Magri and Galli, 2013;
Normand et al., 2013; Prabhakar et al., 2013). These models have
included a variety of drug inducible and non-inducible condi-
tional knockouts, as well as adenoviral-mediated approaches or
in utero electroporation to induce gene knock-out stochastically.
These approaches have allowed for targeted induction of TSC1-
or TSC2-deficiency in distinct neural cell populations, limited by
regional location, the size of the affected cell population, or the
developmental time-point of induction.
Arising from these efforts, mouse models of TSC1- or TSC2-
deficiency now exist that closely model the CNS manifestations
of TSC that occur in human patients, including neuronal net-
work dysfunction and seizure activity, sub-ependymal nodules
that lead to the development of SEGAs and elements of cortical
tubers, accompanied by abnormal neuronal migration, enhanced
astrogliosis, enlarged cells and cortical lamination defects (Goto
et al., 2011;Magri et al., 2011; Carson et al., 2012;Magri and Galli,
2013; Normand et al., 2013; Prabhakar et al., 2013). Importantly,
hyper-activation of mTORC1 signaling has indeed been con-
firmed as causative in the majority of TSC-like phenotypes in
these models, confirmed by extensive phenotypic rescue follow-
ing post-natal Rapamycin treatment in many of these studies.
Interestingly, these models have revealed that while abnormal,
enlarged cells and nodule-like formations can be induced to some
degree by TSC gene deletion in virtually all neuronal populations
(progenitors and post-mitotic cells) and at different developmen-
tal stages (throughout embryogenesis and postnatally), neurolog-
ical features such as seizure activity are only clearly reproduced
by targeting NPCs and neurons prenatally, during peak stages of
neurogenesis. Furthermore, the overall severity of CNS manifes-
tations following TSC gene deletion at different stages occurs on
a gradient scale, with the most severe and extensive phenotypes
associated with mutations in NPC populations at the earliest
stages of neurogenesis (in neuroepithelial cells and radial glia at
E9.5 and E12.5, respectively). As appearance of the full spectrum
of TSC-associated CNS lesions seems to require TSC gene muta-
tion in early NPCs, these studies together provide solid evidence
to support the hypothesis that a neural stem or progenitor cell is
the cell of origin for the CNS manifestations in TSC.
The proportion of TSC1/ TSC2-deficient cells affects phenotypic
severity in mouse models
Not only have the CNS mouse models revealed that TSC gene
deficiency at different stages of neural development can lead
to different types of manifestations, but also that the degree
of mosaicism of TSC1- or TSC2-deficient cells correlates with
phenotypic severity. The first key element in generating mouse
models that closely recapitulate the TSC condition was induction
of TSC gene deficiency in specified neuronal sub-populations, as
opposed to homozygous mutations in ESCs. This demonstrated
that while wide-spread homozygous TSC1- or TSC2-deficiency
within the germline results in overly severe, lethal phenotypes,
restricted TSC gene mutations within the neuronal lineage can
be better tolerated but lead to TSC-like phenotypes in the brain.
Again, mutation at late vs. early developmental stages, in which
fewer downstream cells would be directly affected, leads to less
severe phenotypes.
Some recent mouse models have directly demonstrated exper-
imentally, within distinct cell populations, that the degree of
mosaicism for TSC gene deficiency within neural cells also leads
to a spectrum of phenotypes. Specifically, mutation of TSC1 in
a subset of thalamic progenitor cells caused substantially greater
neurological dysfunction, indicative of TSC-like pathology, if the
mutation was made at mid-gestation (E12.5) vs. late gestation
(E18.5) in an embryonic mouse model (Normand et al., 2013),
and experiments in which subsets of NPCs were knocked-out
for TSC1 in variable numbers using adenoviral-mediated Cre
injection into the cerebral ventricles showed that the severity of
resulting TSC-like pathology was dependent on the dose and
serotype of the injected virus (Prabhakar et al., 2013). These
models have provided strong evidence that the CNS lesions and
neuropathologies associated with TSC can be driven by TSC1- or
TSC2-deficiency and consequent mTOR deregulation in NPCs,
and together demonstrate that the severity of the TSC-associated
CNS phenotypes exist on a spectrum that is strongly influenced
by the developmental timing and degree of mosaicism for TSC1
or TSC2.
HETEROGENEITY IN DISEASE SPECTRUM SUGGESTS DISTINCT CELLS
OF ORIGIN AND POTENTIAL MOSAICISM IN TSC
A clear distinction between individuals with TSC gene mutations
who acquire Tuberous Sclerosis vs. S-LAM is that the somatic
mutations in TSC1 or TSC2 are more widespread in those with
TSC, and are typically also present in the germline (Dabora
et al., 2001; Strizheva et al., 2001). This was a substantial dis-
covery toward our understanding of how S-LAM may develop
in the absence of other TSC manifestations, and pushed forth
the concept that TSC and LAM lesions may develop from differ-
ent founding cell types, and thus that TSC gene mutations are
restricted to a smaller population of cells in S-LAM patients. The
fact that there is considerable heterogeneity in the clinical pre-
sentation and severity of the disease spectrum among both LAM
and TSC patients (Henske and McCormack, 2012; Curatolo and
Maria, 2013) and evidence for gonadal and/or somatic mosaicism
in some TSC patients that can correlate with phenotypic vari-
ability (Rose et al., 1999; Verhoef et al., 1999; Qin et al., 2010b;
Boronat et al., 2014a,b) lend further support to the concept that
disease spectrum is significantly affected by the proportion of
cells, and likely the identity and fate of those cells, that possess
a TSC gene mutation.
It is also possible that distinct TSC1 or TSC2mutations present
in different patients may also contribute to disease heterogeneity
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by encoding TSC proteins with varying degrees of function.
Indeed, hypomorphicmutations have been observed in some TSC
patients, and experimental and clinical evidence suggest that these
mutations result in reduced phenotypic severity (Khare et al.,
2001; O’Connor et al., 2003; Nellist et al., 2005, 2008; Jansen et al.,
2006; Pollizzi et al., 2009; Yuan et al., 2012; Fu and Ess, 2013).
However, these cases appear to represent a minority of known
TSC patients. Nevertheless, in cases where a hypomorphic TSC
gene mutation is present, it is likely that this feature acts in con-
junction with the identity and proportion of cells that carry the
mutation to influence phenotypic severity.
The findings from the TSC CNS-related mouse models dis-
cussed above provide strong experimental support for the concept
presented here. Although these studies were limited to the CNS
manifestations, it is likely that this theme persists throughout the
full spectrum of the disease and that in general a more restricted
mutational burden will lead to the development of fewer types
of lesions and fewer numbers of lesions. With this in mind, one
could postulate that while TSC gene mutations in NSCs lead
to the CNS lesions, mutations within the neural crest lineage
are responsible for the development of most other TSC lesions,
including those associated with LAM, and that variable muta-
tional burden within the neural crest (NC) lineage leads to the
greatest heterogeneity in TSC disease phenotypes.
EVIDENCE SUPPORTING A NEURAL CREST CELL OF ORIGIN FOR LAM
AND OTHER TSC-ASSOCIATED LESIONS
Neural crest cell activity during embryogenesis
The neural crest is a transient population of migratory progen-
itor cells that emerge at the interface between the dorsal region
of the neural plate and the non-neural ectoderm in embryonic
development during neurulation. Although the migratory pat-
terns of the NC can differ slightly from species to species, studies
performed in model organisms, such as Xenopus, mouse, quail
and chick embryos, have offered great insight into the contri-
butions of the NC population to various tissues in the devel-
oping embryo. Although exact migratory patterning in humans
is unknown, lineage tracing has revealed enough commonality
between these model species to establish a paradigm for neu-
ral crest cell (NCC) migration and differentiation during human
development. Through contact mediated interactions, NCCs
emerge, undergo epithelial-to-mesenchymal transition (EMT),
and migrate in specific succession and order in an anterior to
posterior sequence (Theveneau and Mayor, 2012). Of note, both
the neural plate and the surface ectoderm contribute cells to
the NC population (Moury and Jacobson, 1990; Selleck and
Bronner-Fraser, 1995). Once NCCs have emerged and delam-
inated, they follow distinct migratory patterns depending on
their eventual fate, the majority of which are summarized in
Table 1.
NCCs can be generally categorized into four major subgroups
based on their migratory cohort: cranial, cardiac, vagal and trunk.
Cranial NCCs contribute to the tissues of the craniofacial region,
differentiating into the widest array of cell types of the neural crest
subgroups, including vascular smooth muscle cells and pericytes,
chondrocytes, adipocytes, osteocytes, odontoblasts, melanocytes,
connective tissue, and sensory and parasympathetic ganglia
Table 1 | Neural crest cells can be categorized into four
major subgroups, based on their respective migratory pattern and
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It should be noted that individual NCC multipotency varies between subgroups
as well as within subgroups themselves.
(D’Amico-Martel and Noden, 1983; Köntges and Lumsden, 1996;
Etchevers et al., 2001; Billon et al., 2007; Grenier et al., 2009).
Cardiac NCCs differentiate into parasympathetic cardiac gan-
glia, as well as smooth muscle of the branchial arches and the
cardiac outflow tract, and form the aorticopulmonary septum
(Kirby et al., 1983; Kirby and Stewart, 1983). Vagal NCCs pri-
marily give rise to the neurons and glia of the enteric nervous
system (Yntema and Hammond, 1954; Le Douarin and Teillet,
1973). Finally, trunk NCCs give rise to melanocytes and the neu-
rons and glia of the peripheral nervous system (Raible and Ungos,
2006).
Potential role for neural crest subtypes in TSC disease
heterogeneity
NCCs are able to differentiate into a wide array of cell types that
contribute to many of the tissues associated with TSC tumors.
Theoretically, distinct NC subtypes could be specifically associ-
ated with some of the multi-systemic tumors observed in TSC.
For instance, the cranial NC may be implicated in the devel-
opment of facial angiofibromas, dental pits, and retinal tumors.
Indeed, cases of retinal lesions have been reported in connection
with neurofibromatosis, a disease also thought to be of neural
crest origin (Ishiko et al., 2006; Sachdeva et al., 2010). Cortical
tubers could also potentially be attributed to the cranial neural
crest, a theory that has previously been postulated (Hindman
et al., 1997). Extending this theory, TSC1- or TSC2-deficient
cardiac NC may be the cell of origin for cardiac rhabdomy-
omas and even pulmonary LAM lesions (due to the involvement
in aorticopulmonary septum development), and dysfunctional
trunk NC may be responsible for “confetti” skin lesions and
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hypomelanotic macules. Within this frame of thought, the deter-
mining factor in which tumor types ultimately form is per-
haps both spatial and temporal. If the first-hit mutation occurs
early on during embryogenesis within a cell of the develop-
ing neural plate or surface ectoderm before neurulation, the
potential number of affected progeny capable of acquiring a
second-hit mutation would be much greater and could poten-
tially affect all NC subgroups, leading to a more severe TSC
phenotype affecting multiple tissues. If the first-hit mutation
occurs later in development, perhaps in an emerging NC sub-
type, the affected cell may only have influence on the specific
subtype emerging from its respective anterior/posterior posi-
tion along the developing neural tube. Such a scenario could
explain the extreme differences in TSC disease spectrum that
are observed in highly affected TSC patients vs. individuals with
S-LAM.
Neural crest stem cells persist in adult tissues associated with TSC
lesions
While tissue innervation by migrating NCCs is a fundamental
process during embryonic development, NCCs with stem cell-like
properties are now known to persist in a number of adult tissues.
Just as tissues that are innervated by embryonic NCCs during
development theoretically have the potential to give rise to LAM-
like cells or cells that comprise other TSC mesenchymal lesions,
these adult neural crest stem cells (NCSCs) are a particularly
promising population as a potential LAM and TSC cell of origin.
The tissues in which NCSCs reside in the adult are diverse, and
include the gut, bone marrow, heart, dental mesenchyme, dor-
sal root ganglia, and cornea (reviewed in Dupin and Sommer,
2012). Intriguingly, a number of distinct multipotent stem cells
with neural and/or NC differentiation potential have also been
identified in the skin (Dupin and Sommer, 2012). As NCCs pos-
sess inherent migratory and transdifferentiation potential (dis-
cussed further below), and exhibit extensive interactions with
their surrounding microenvironments that can instruct migra-
tory, differentiation and invasiveness behaviors, many of these cell
types could potentially serve as the cell of origin for TSC lesions
(Takahashi et al., 2013).
The susceptibility of the skin to ultraviolet (UV) radiation
implicates resident skin NCSCs as promising cell of origin candi-
dates, as UV-induced damage could induce second-hit mutations.
For example, skin-derived precursors (SKPs), multipotent NCSCs
found in the dermal sheath and papillae of hair follicles in both
rodents and humans (Toma et al., 2001, 2005; Fernandes et al.,
2004; Biernaskie et al., 2009; Jinno et al., 2010), have been heavily
implicated as the cell of origin for the dermal tumors associated
with the neurocristopathic disorder Neurofibromatosis type I (Le
et al., 2009). A recent study has also provided compelling evidence
that precursor cells found within the skin may serve as the cell
of origin for facial angiofibromas in TSC patients, following the
acquisition of UV-induced second-hit TSC2mutations (Tyburczy
et al., 2014). Given this potential, it is a distinct possibility that
SKPsmay similarly serve as the cell of origin for LAM and the cells
that comprise other TSC-associated lesions, providing that SKPs
possessing TSC gene mutations are able to invade the lymphatic
and/or cardiovascular circulation.
Clinical evidence suggests a neural crest origin for TSC and LAM
lesions
Sequencing of tissue from LAM nodules or disseminated LAM
cells from body fluids has indicated that germline TSC1 or TSC2
mutations are not prevalent in S-LAM patients (Astrinidis et al.,
2000; Carsillo et al., 2000). Thus, the first-hit mutation that drives
LAM must typically arise de novo in a somatic cell. The lack of
CNS involvement in the pathology of S-LAM provides strong
clinical evidence that the neural stem cell lineage is not affected
in S-LAM patients. The molecular markers present in LAM cells
within its classical lesions [alpha-SMA, HMB-45, TRP-1, MART-
1, GD3 (Carbone, 2009; Gilbert et al., 2013)], as well as the tissue
types affected in the majority of TSC-associated tumors, do how-
ever present significant clues to the potential cell(s) of origin.
The tissues in which lesions/abnormalities are observed in TSC
patients are diverse, but all of them share the common feature
that they are wholly or in part comprised of neural crest progeny
(Figure 1, Table 1) (Dupin and Sommer, 2012). These tissues
include the heart (cardiac rhabdomyomas), the skin (angiofi-
bromas, most predominant in the facial region), dental enamel,
eyes (retinal astrocytic hamartomas), and the innervation of the
kidneys (AMLs), uterus and lungs (Curatolo and Maria, 2013).
Additionally, the abnormal cells observed in LAM lesions express
molecular markers of cells that are generated by the neural crest;
these include smooth muscle, melanocytes, and adipocytes.
In addition to key molecular markers, there is also compelling
evidence that TSC and LAM cells are able to migrate between
different tissue sites (Smolarek et al., 1998; Karbowniczek et al.,
2003), reminiscent of the highly migratory behavior of neural
crest cells. Furthermore, LAM lung lesions contain a heteroge-
neous population of cells, with both highly proliferative spindle
shaped cells and large epithelial cells making up LAM clusters.
Moreover, both of these cell types express molecular markers of
mesenchymal neural crest cells in vivo (e.g., smooth muscle actin,
and HMB45 or gp100 in the epithelial cells). This suggests the
intriguing possibility that, if indeed LAM cells originate from
the neural crest, they may possess the ability to undergo EMT
or even mesenchymal-to-epithelial transition (MET) within the
lesion itself, accounting for the presence of these distinct cell types
within single lesions.
LAM cells exhibit extensive migration and EMT
Just as neural crest cells represent a highly migratory cell popula-
tion, a striking characteristic of LAM cells is their ability to travel
from one tissue site to another, leading to multi-tissue tumor
formation. For example, mutation analysis has revealed that the
samemutations are present in LAM cells of both pulmonary LAM
nodules and AMLs, indicating that the tumors originated from
a common progenitor cell that was able to migrate or metas-
tasize to and/or from either of these tissues (Sato et al., 2002).
Although identical TSC1 or TSC2 mutations among tumor cells
are not always observed in TSC-LAM and S-LAM patients, it is
clear that LAM cells are mobile; markedly, LAM cells are able to
infiltrate and repopulate healthy donor lungs following transplan-
tation (Bittmann et al., 2003; Karbowniczek et al., 2003). They
are also are able to metastasize between the lungs, kidneys, lym-
phatics, and uterus using mechanisms that do not fit the classic
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cancer metastasis paradigm. LAM cells can be found throughout
the lymphatics in LAM patients, and their expression of VEGF-C
and VEGF-D along with VEGF receptor-3 indicates their lym-
phangiogenic potential (Glasgow et al., 2012), indicating that the
extensive network of lymphatics may serve as the primary niche
for LAM cells and facilitates their spread.
LAM cells do not easily succumb to anoikis and can be found
in the chylous fluid, urine, and circulating in the blood of LAM
patients, a phenomenon that may be directly related to estrogen
signaling (Crooks et al., 2004; Yu et al., 2009; Gu et al., 2013).
Although these cells do not present themselves as malignant or
highly proliferative compared to most cancer cells, their apparent
robustness and infiltrative ability is certainly not benign.
A complete mechanistic model for LAM cell “metastasis” has
yet to be confirmed; however, numerous studies have shown
that LAM cells display increased motility and invasive proper-
ties in vitro. This invasive phenotype can be directly linked to
loss-of-function mutations in either TSC1 or TSC2, leading to
pro-migratory cytoskeletal rearrangement and changes in focal
adhesions. Primary LAM cells with TSC2 loss-of-function muta-
tions display increased invasive and migratory properties as a
result of RhoA GTPase-mediated cytoskeletal rearrangement and
modulation of focal adhesions. RhoA GTPase is normally reg-
ulated by TSC1 when complexed with TSC2, and this invasive
phenotype is mitigated upon TSC2 re-expression or TSC1 knock-
down (Lamb et al., 2000; Goncharova et al., 2006). Perhaps
contributing to the robustness of migratory LAM cells, dysfunc-
tional TSC2 leads to a loss in membrane bound E-cadherin via
a Rapamycin sensitive pathway. This, in turn, leads to reduced
cell-cell adhesion, EMT, cell detachment, and resistance to anoikis
(Barnes et al., 2010).
Molecular features and behavior of LAM cells parallel the neural
crest
Clearly, dysfunction of either TSC1 or TSC2 will result in a cell
that is primed to undergo EMT and migrate, a scenario that
is reminiscent of neural crest delamination and migration dur-
ing embryonic development. RhoA is critical in regulating the
directionality of migrating neural crest cells, greatly affecting
spatial-temporal patterning upon its loss (Rupp and Kulesa, 2007;
Matthews et al., 2008). Cadherins play a crucial role during neu-
rulation and help define the non-neural ectoderm and the neural
plate (Taneyhill, 2008; Dady et al., 2012), the tissues whose inter-
face fromwhich neural crest cells delaminate and fromwhich they
migrate. Specifically, the transition from E-cadherin expression to
N-cadherin plays a critical role in this process, and interestingly,
a similar phenomenon is observed in LAM cells. As mentioned
above, TSC2-deficiency results in internalization of E-cadherin
leading to EMT; moreover, when LAM patient-derived cells are
exposed to estrogen, E-cadherin expression is decreased and N-
cadherin is upregulated, similar to the segregation of the germ
layers during neurulation (Gu et al., 2013). Pairing well with
the decrease in E-cadherin expression in TSC2-deficient cells,
there is an upregulation in the expression of Snail, an important
transcription factor involved in initiating EMT, migration, and
neural crest specification (Cano et al., 2000; Aybar et al., 2003;
Barnes et al., 2010). A second-hit mutation in TSC2 therefore
causes a change in the expression profile in LAM cells that resem-
bles a neural crest progenitor undergoing migration and fate
specification.
Adding fuel to the fire, LAM cells have been shown to excrete
matrix metalloproteinases (MMPs), particularly MMP-2 and
MMP-9, that likely contribute to their invasiveness and lead to
the slow destruction of the lung parenchyma (Hayashi et al., 1997;
Lee et al., 2010a). MMP2 and MMP9 are required in neural crest
cells for their initial delamination and migration, and inhibition
of these MMPs during development results in the complete halt
of NC migration and differentiation (Monsonego-Ornan et al.,
2012).
Extending this comparative train of thought, changes in TGF-
ß signaling in LAM cells also relates directly to the NC and
its lineages. Histopathological analysis of LAM cells, along with
TSC2-null cell lines, show increased levels of TGF-ß and smooth
muscle actin (SMA) (Zhe and Schuger, 2004; Barnes et al., 2010;
Lee et al., 2010a). Although expression of TGF-ß and SMA is
common to the EMT process, TGF-ß signaling is involved in NC-
derived smooth muscle specification in vivo and is a common
element of smooth muscle differentiation protocols of neural
crest cells in vitro (Shah et al., 1996; Curchoe et al., 2010; Xie et al.,
2013). The initiation of signaling cascades resulting in a smooth
muscle-like cell fate may help explain the presence of spindle-like
SMA+ proliferative cells in LAM nodules and angiomyolipo-
mas. A loss of TSC2 function could destabilize a NC-derived cell,
causing it to dedifferentiate and undergo EMT. This cell could
then potentially migrate to a favorable niche (e.g., lung, kidney,
lymphatics) and, due to increased TGF-ß signaling, differentiate
into the smooth muscle cells and form the characteristic tumors
associated with LAM.
The molecular signaling events that occur upon a second-hit
mutation in TSC1 or TSC2 may act in some capacity to reca-
pitulate the developmental processes of neural crest migration
and specification. Such an orchestration may be enough to per-
haps destabilize a dormant NCSC or a fully differentiated NC cell,
whose epigenetic memory is already prone to EMT, migration,
and cell motility. Indeed, with the proper stimulus, fully differ-
entiated NC progeny display the ability to dedifferentiate and
migrate in vivo, as well as return to a multipotent state when iso-
lated and cultured in vitro (Real et al., 2005, 2006; Nagoshi et al.,
2011; Dupin and Sommer, 2012).
The NC has already been implicated in the reactivation of
EMT in fully differentiated and mature cells in the form of the
metastatic cancers melanoma and neuroblastoma (Grimmer and
Weiss, 2006; Shakhova, 2014). Furthermore, dedifferentiation
and redifferentiation (EMT-MET switch) is a proposed mecha-
nism of metastatic cancer supported by experimental evidence
(Ocaña et al., 2012; Tsai et al., 2012). Neural crest cells have the
unique ability to transdifferentiate during embryonic develop-
ment from a neural ectodermal lineage to specialized cells that are
ultimately considered to be mesodermal. This phenotypic plas-
ticity is a unique quality of the neural crest, which clearly requires
precise signaling and environmental cues during development for
precise specification. Similar to the notion that a machine with
many small moving parts is more likely to malfunction, neural
crest-derived cells may be more prone to undergo EMT, migrate,
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and differentiate based on their inherent plasticity if given the
proper cues.
Current models to investigate neural crest contribution to TSC
Few studies have directly investigated the hypothesis that TSC1
or TSC2 mutations in neural crest stem cells drive the develop-
ment of non-CNS tumors in TSC, including LAM. Mice con-
taining a conditional TSC1 knockout allele crossed with mice
expressing Cre driven by the WNT1 promoter die prenatally, for
unknown reasons, with no indication of renal or lung pathology
(Kwiatkowski, 2010). No additional mouse or cell culture-based
models of TSC1 or TSC2-deficiency in the neural crest lineage
have been reported to date. The lack of clarity provided by exist-
ing mouse models, and the paucity of such models, regarding
the development and progression of LAM in humans, heavily
underscores the need for improved models that more closely
recapitulate human pathology.
It is quite possible that the biology of TSC1- or TSC2-
deficiency is substantially different in mouse vs. human NCCs,
and that establishing the samemodels (e.g., Wnt1-cre conditional
models of TSC1/2-deficiency) in a humanized system will allow
us to generate accurate disease models. Alternatively, the lethal-
ity of the Wnt1-cre TSC1 knockout mouse model may also serve
as an indicator that homozygous TSC gene deletions within the
neural crest lineage are not compatible with embryonic develop-
ment and that TSC-like phenotypes will only be observed under
conditions where second-hit mutations can be induced in a con-
trolled manner within sub-populations of cells. Speaking to this,
it is possible that different tumor types that are prevalent in TSC
patients, as well as those that define LAM disease, are derived
from TSC1- or TSC2-deficient cells of different neural crest sub-
types. Identification of the NCC subtype(s) responsible for the
development of LAM tumorsmay importantly result in less severe
phenotypes and prolonged survival in animal models that should
enable longer-term experiments to be performed than have been
possible with current models. Additionally, this will inevitably
result in disease phenotypes more specific to the LAM condition,
allowing us to generate the most appropriate models possible.
STRATEGIES FOR GREATER UNDERSTANDING AND IMPROVED
TREATMENT OPTIONS IN TSC AND LAM
Theoretical model of neural crest contribution to disease
heterogeneity
While there is extensive correlative evidence for a potential role
of the NC lineage as the cell of origin for LAM and many
TSC manifestations, this hypothesis remains to be adequately
tested experimentally. We present a model (Figure 2) whereby the
diverse, heterogeneous tumor burden in TSC patients is depen-
dent on when first- and second-hit mutations in TSC1 or TSC2
occur during development and into adulthood. In this model,
mutations that are carried in the germline or that are acquired
during early stages of embryogenesis lead to a greater disease
burden than those that occur at later time points. For instance,
the majority of TSC patients have germline mutations, and thus
all cell lineages, including both neural and neural crest progen-
itors, are vulnerable to the acquisition of second-hit mutations.
Second-hit mutations may occur independently within the neural
and neural crest lineages, or perhaps in a cell very early in devel-
opment (i.e., before neurulation) (Figure 2A). In any case, TSC
patients that carry a germline TSC1 or TSC2 mutation are likely
to acquire wide-spread and severe disease manifestations due to
the diverse pool of progeny susceptible to acquiring second-hit
mutations (i.e., both the NCC and NSC lineages).
Similarly, a first-hit mutation acquired at a time point as
early as neurulation (Figure 2A) would give rise to sporadic TSC,
explaining the genotypic mosaicism observed in some patients.
In this scenario, the severity of the resulting disease spectrum
depends on the distribution pattern of “first-hit” cells into down-
stream lineages as well as in which cell populations second-hit
TSC gene mutation(s) are acquired. Here, both the NCC and
NSC lineages are vulnerable to being infiltrated by TSC mutant
cells, however mosaicism may lead to reduced disease severity by
restricting the number of cells or the cell lineages that carry TSC
mutations.
Following this model further, the more limited disease man-
ifestations observed in S-LAM, and potentially milder forms of
TSC, would originate from a primary TSC gene mutation in a
much more restricted population limited to the NC lineage. This
could occur either during embryogenesis within a common or
sub-type restricted neural crest progenitor cell (Figure 2B) or
in adulthood (Figure 2C), affecting NCSCs or NC-derived cells,
such as melanocytes or SKPs. The former possibility could fore-
seeably occur either via mosaicismwithin the broader NC lineage,
in which only certain NC subtypes carry enough of a mutational
burden to drive the development of a lesion, or restriction of first-
and/or second-hit mutations within a functionally defined sub-
population of NC. A likely candidate is the cardiac NC lineage
due to its involvement in development of the aorticopulmonary
septum. In either scenario, only cells that were derived from
NCCs during development or NCSCs that persist in adult tis-
sues are vulnerable to a second-hit mutation later in life that may
endow them with the ability to drive the formation of TSC and
LAM lesions. This highlights the possibility that the heterogeneity
within TSC and S-LAM patients is predominantly dictated by the
cells that carry a first-hit TSC gene mutation and, consequently,
the resulting progeny left vulnerable to acquiring a second-hit
mutation.
As mosaicism within the NC lineage may potentially lead to
the more restricted phenotypes associated with LAM, so too may
gonadal or somatic mosaicism lead to varying degrees of phe-
notypic severity in TSC patients, as has been observed clinically
(Rose et al., 1999; Verhoef et al., 1999; Qin et al., 2010b; Boronat
et al., 2014a,b). This type of model is therefore likely to underlie
phenotypic differences between TSC vs. LAM alone, as well as the
heterogeneity in disease features observed in both TSC and LAM
patient cohorts themselves. Thus, a TSC1 or TSC2mutation at an
earlier developmental stage has the potential to result in a more
complete spectrum of TSC phenotypes, while a later mutation
will lead to a more restricted pathological potential, resulting in
limited TSC phenotypes or LAM only.
Current treatment options for TSC and LAM
While double lung transplant is currently the gold standard treat-
ment option for LAM, this approach is not possible in all patients;
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FIGURE 2 | Model illustrating that the variation of tumor heterogeneity
in TSC may be related to the stage of development in which loss of
function mutations in TSC1 or TSC2 occurs. (A) For TSC patients with
germline mutations, second-hit mutations may be acquired during early
stages of embryogenesis, such as during gastrulation or neurulation. This
would result in a large population of cells that carry the mutation and
would lead to a severe TSC phenotype, possibly displaying the full
spectrum of TSC manifestations. First-hit mutations at this time point
would result in mosaicism. The affected cells could contribute not only to
the neural crest lineage, but also the neural progenitor population of the
neural tube, resulting in the CNS manifestations of TSC. (B) Second-hit
mutations occurring in the emerging neural crest population likely results
in many of the non-CNS symptoms of TSC, potentially including LAM.
First-hit mutations at this time-point may result in S-LAM, as only the
neural crest lineage would be vulnerable to second-hit mutations. It is
possible that a sub-population of NCCs, such as the cardiac NC, is
responsible for the more restricted lesions associated with S-LAM.
(C) Alternatively, first- and/or second-hit mutations acquired within an adult
NCC could also be responsible for driving LAM and some TSC-associated
lesions (e.g., skin lesions).
additionally, LAM lesions have been shown to recur in the donor
lung in some patients (Bittmann et al., 2003; Karbowniczek
et al., 2003). Thus, transplantation does not address the under-
lying mechanisms that drive the development of LAM cells and
associated lesions. The mTOR-specific inhibitor Rapamycin is
a promising molecular intervention currently under intensive
investigation as a potential treatment for LAM and other man-
ifestations in TSC. Rapamycin has proven clinically effective for
the treatment of most TSC-associated lesions (Franz et al., 2006;
Bissler et al., 2008; Krueger et al., 2010;Micozkadioglu et al., 2010;
Casanova et al., 2011; Dabora et al., 2011; DeKlotz et al., 2011;
Tiberio et al., 2011; Canpolat et al., 2014; Park et al., 2014), and in
the context of LAM can lead to reduction in the size of AMLs, pro-
vide stabilization of lung function, and a marked improvement in
quality of life measures (McCormack et al., 2011).
A major caveat with this approach, however, is that Rapamycin
is tumoristatic rather than tumoricidal. Thus, disease progres-
sion resumes once Rapamycin is withdrawn. Therefore, patients
must remain on the drug permanently to provide sustained
treatment. Long-term Rapamycin treatment is also not without
potential challenges, as there is concern that LAM tumors, as
well as other TSC lesions, may become refractory to Rapamycin
over an extended time period. Additionally, while Rapamycin
treatment can reduce mTOR signaling, it may also have the
undesirable effect of promoting the survival of TSC1 or TSC2-
null cells (reviewed in Henske and McCormack, 2012). In this
regard, one of the key downstream processes controlled by
mTORC1 signaling is autophagy (Laplante and Sabatini, 2012),
a key cellular survival mechanism, and inhibition of autophagy
is a typical consequence of TSC1- or TSC2-deficiency (Crino
et al., 2006; Parkhitko et al., 2011; Crino and Tsai, 2012; Henske
and McCormack, 2012). Thus, while Rapamycin appears to gen-
erally inhibit the growth of TSC1- or TSC2-deficient cells, it
may concurrently promote their survival by inducing autophagy.
Rapamycin has also been shown to induce expression of pro-
survival micro-RNAs (Trindade et al., 2013). Thus, Rapamycin
treatment may therefore result in a precarious situation whereby
the growth and proliferation of TSC1- or TSC2-deficient cells
is halted, but the cells remain alive in situ, allowing them to
re-expand once treatment is stopped or an alternative mTOR
signaling pathway is triggered in the extensive mTOR signaling
network to bypass mTORC1 inhibition.
As long-term Rapamycin treatment carries a significant
risk of acquired treatment resistance and adverse side-effects
(McCormack et al., 2011), additional therapeutic options are
needed to provide life-long treatment options to TSC and LAM
patients. Importantly, a number of proteins thought to be impor-
tant in LAM pathogenesis are unaffected by Rapamycin treatment
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in LAM cells, including MMP2 (Lee et al., 2010b). Due to this
fact and observations that alternative pathways are activated by
Rapamycin treatment that promote cell survival, there is a strong
indication for the development of alternative or combination
therapies. Thus, the development of new therapeutic approaches
is currently of the highest priority within the LAM and TSC fields.
In concert with this, the development of effective models to aid in
the identification and testing of potentially effective therapeutic
interventions must also be at the top of the list.
Identification of the cell of origin for LAM and other TSC-
associated tumors is imperative for the development of more
effective, long-lasting treatment strategies. Only by inducing first-
and second-hit mutations in the proper cell of origin, and in
the proper proportion of that population, will we be able to
fully understand and therapeutically target the molecular mech-
anisms that drive the initiation and progression of distinct TSC
lesions. mTOR activation can lead to different primary pheno-
types in distinct cell types, such as precocious differentiation in
the CNS (Hartman et al., 2013), increased cycling of hematopoi-
etic stem cells (Gan et al., 2008), and exit of satellite cells from
quiescence upon injury (Rodgers et al., 2014). Therefore, different
TSC-associated lesions may require different targeted therapeu-
tic approaches. Furthermore, the downstream targets of mTOR
are diverse and affect multiple cellular signaling pathways, and
mTOR participates in a number of feed-back signaling mech-
anisms (Laplante and Sabatini, 2012). Due to this complexity,
truly effective treatment approaches are likely to require combina-
tion therapies in which multiple signaling nodes are targeted, and
the most promising approaches may well be different for distinct
tumor types.
A need for humanized disease models
The TSC and LAM fields have benefited significantly from cell
culture-based and rodent models of TSC1- or TSC2-deficiency;
however, these models carry a number of caveats. Rodent mod-
els of spontaneous (e.g., the Eker rat) or genetically engineered
TSC gene deficiency, and cells cultured from these animals (e.g.,
ELT3 cells, isolated fibroblasts), have offered important insights
into the basic molecular and cellular phenotypes caused by TSC
ablation and have provided avenues for experimental drug test-
ing. However, these models do not fully recapitulate the tumor
spectrum or phenotype of many TSC lesions or their deriva-
tive cells, including LAM. While these animal models exhibit a
high penetrance of renal cystadenomas and liver hemangiomas
with age, and a partial penetrance (about 30%) of lung adeno-
mas, these tumors do not recapitulate the phenotypes of those
observed in human TSC patients (Kobayashi et al., 1999, 2001;
Onda et al., 1999; Kwiatkowski et al., 2002; Kwiatkowski, 2010).
Therefore, they cannot be used to understand the pathophysiol-
ogy of themost clinically significant manifestations of TSC, nor as
accurate pre-clinical models for drug testing to treat or eliminate
these lesions.
Presently, there is a lack of humanized-models of TSC and
LAM. Primary TSC1- or TSC2-deficient cells from TSC or LAM
patients unfortunately cannot be efficiently propagated in cul-
ture without viral transformation, and even then some elements
of LAM cell identity observed in vivo are not recapitulated in
culture. Additionally, patient-derived cells lack proper control cell
lines, and induction of TSC1- or TSC2-deficiency (disruption of
both alleles or a high-degree mRNA knockdown), as is the case
for most of the existing models, bypasses mechanisms that lead
to second-hit mutations. As this important feature of TSC and
LAM tumor pathogenesis is absent, these systems cannot be used
to understand the processes leading to tumor induction and sub-
sequent disease progression. Thus, to accurately model TSC and
LAM it will be essential to generate or obtain human cell lines in
which first- and second-hit TSC gene mutations can be induced
in a controlled manner, and in which cellular phenotypes can
be clearly assessed following differentiation into putative cell of
origin lineages. Identification of the cell types of origin for TSC
and LAM lesions is an essential step toward the development
of accurate pre-clinical humanized disease models. Such mod-
els will not only allow for a more relevant understanding of the
mechanisms that drive disease, but will also greatly improve ther-
apeutic options for patients, making personalized therapeutics a
potentially viable option for TSC.
Approaches for generating humanized disease models
While it is clear from mouse models that it is at least possible to
induce TSC-like brain lesions by manipulating mTOR signaling
in the NSC lineage, no humanizedmodels exist to test whether the
same events are indeed responsible for driving CNS pathologies
in humans. Furthermore, while a NC origin for non-CNS lesions
in TSC seems intuitive, direct experimental evidence testing this
hypothesis in human cells is needed. To perform these pivotal
experiments, we need better disease models. First, we need to gen-
erate human cell lines that will recapitulate phenotypes observed
in distinct TSC and LAM lesions, and can potentially give rise
to these lesions in vitro and in in vivo mouse models, follow-
ing controlled induction of TSC1- or TSC2-deficiency. Second,
the behavior of the cells that comprise TSC lesions appears to be
highly dependent on interactions with their tissue microenviron-
ment. Thus, proper diseasemodels should incorporate in vivo and
in vitro culture-based approaches that closely recapitulate the nat-
ural, in situ environment in which TSC and LAM lesions normally
develop.
One promising approach for the generation of humanized
models in TSC is to couple genetic engineering to induce TSC1/2-
deficiency with embryonic stem cell (ESC) or patient-derived
induced pluripotent stem cell (iPSC) technology. ESCs and iPSCs
are pluripotent stem cell populations that have the capacity to
differentiate into any cell type found in the body, including can-
didate cell types of origin for TSC and LAM lesions. Furthermore,
iPSCs importantly offer an avenue for patient-specific model-
ing, as it allows fully differentiated cells from TSC and LAM
patients harboring TSC gene mutations to be reprogrammed to
an ESC-like state, enabling subsequent directed differentiation
into putative cell of origin populations.
Directed differentiation of human ESCs or iPSCs into neural
and neural crest lineages in vitro and in vivo, coupled with the
ability to inducibly knock-out or knock-down TSC1 or TSC2 at
different stages of differentiation, will directly allow cell of origin
theories to be tested. This will also allow for the establishment of
human cell lines that reflect TSC and LAM cell phenotypes and,
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following in vivo injection of TSC1/2-deficient cell lines, the gen-
eration of humanized animal models of LAM and TSC lesions.
Subsequently, growth and differentiation of these cell lines in not
only 2-dimensional, but also 3-dimensional culture conditions, as
well as injection into immune-compromised mice, will enable the
behavior of these cells to be studied in environments that more
closely recapitulate the in vivo environment of distinct TSC and
LAM lesions.
A second, highly promising approach that would offer oppor-
tunities for patient-centered discovery and treatment is to use
endogenous sources of NC-like stem cells resident within adult
tissues, such as SKPs, to generate TSC1- or TSC2-deficient lines.
SKPs reside in a location that is highly accessible for tissue
extraction and subsequent NC cell isolation, thus they may
be a particularly useful cell population to allow for the devel-
opment of patient-specific models. Development of models in
which a patient’s own cells can be used as the source mate-
rial to follow disease initiation and progression will importantly
allow us to understand not only the basic mechanisms of TSC
and LAM tumor formation, but also what drives the hetero-
geneous phenotypes that are often observed between different
patients.
CONCLUSION
The TSC and LAM research communities have moved at an
impressive pace in the last two decades. Since discovering
the TSC2 gene in 1993 (European Chromosome 16 Tuberous
Sclerosis Consortium, 1993), investigative research efforts have
quickly produced a plethora of experimental data leading to
the development of the first generation of therapeutics for TSC
and LAM. However, due to the pitfalls associated with the
largely tumoristatic action of Rapamycin and closely associated
“rapalogs,” it is apparent that a wider array of advanced treat-
ment options is necessary to combat these multisystem disorders.
Current disease models of TSC and LAM have been invaluable
in providing insight into molecular disease pathology, provided
a basis for clinical trials of rapalogs and other potential thera-
peutics, and has supported the investigation of neural stem cell
of origin theories for TSC CNS manifestations. However, these
same disease models have their limitations and do not fully reca-
pitulate the nature or progression of TSC and LAM observed in
humans.
There is sufficient evidence to suggest that the NC lineage is
integrally involved in TSC and LAM tumor heterogeneity; how-
ever, this notion has largely been limited to discussion due to
a lack of an effective means to study such theories. Currently,
there are no humanized models of TSC and LAM that provide
a framework for investigating this theory, nor to investigate the
influence of TSC gene mutations acquired during early develop-
ment on disease heterogeneity. Yet, with the current advances in
tissue culture methods, stem cell-based disease modeling, and the
advent of iPSC technology, this will likely change in quick order.
Using humanized models to identify the cell of origin for LAM
and other TSC tumors is crucial in identifying and targeting the
specific molecular mechanisms responsible for distinct TSC and
LAM lesions, and will help pave the way for the next generation
of TSC and LAM therapeutics.
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